🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,418 results for “1” Clear

  1. 610

    Sunshine Biopharma

    Asthma

    phase 3 small molecule active

    2 trials

  2. 611

    Sunshine Biopharma

    Sinusitis

    phase 3 small molecule active

    2 trials

  3. 611

    Sunshine Biopharma

    Dermatitis, Atopic

    phase 3 small molecule active

    3 trials

  4. 611

    Sunshine Biopharma

    Pulmonary Disease, Chronic Obstructive (COPD)

    phase 3 small molecule active

    1 trial

  5. 64Cu(II)Cl2 solution for injection, Fluorocolina (18F) Curium Italy 225 MBq/mL soluzione iniettabile

    A.C.O.M. - Advanced Center Oncology

    Prostate cancer at risk of developing metastatic lesions

    phase 3 small molecule active

    1 trial

  6. 64Cu-PSMA I&T

    Curium Romania S.R.L.

    Prostate cancer

    phase 3 small molecule active

    1 trial

  7. 68Ga-PSMA-11

    Telix Innovations

    PCA

    phase 3 small molecule active

    1 trial

  8. 68Ga-PSMA-11

    China SXT Pharmaceuticals

    Biochemical Recurrence of Malignant Neoplasm of Prostate

    phase 3 small molecule active

    1 trial

  9. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  10. 89Zr-CED88004S

    Disc Medicine

    Large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  11. A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

    Pharma Mar S.A.

    Lewy body Dementia psychosis (LBDP)

    phase 3 other active

    1 trial

  12. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Roche Registration Limited

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  13. A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis

    Roche Registration Limited

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 other active

    1 trial

  14. A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy

    Roche Registration Limited

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  15. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

    Roche Registration Limited

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  16. A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

    Roche Registration Limited

    KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 other active

    1 trial

  17. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen Technology (Ireland) UC

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  18. A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial

  19. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  20. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

    GlaxoSmithKline Biologicals S.A.

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  21. A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)

    Disc Medicine

    ABC borderline resectable pancreatic cancer

    phase 3 other active

    1 trial

  22. A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 other active

    1 trial

  23. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline Biologicals S.A.

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  24. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources